The Illinois Department of Public Health has begun distributing a new COVID-19 treatment designed for use in adults with mild to moderate cases who are at risk for serious illness.
The new treatment, known as bebtelovimab, is a monoclonal antibody that received an emergency use permit from the Food and Drug Administration earlier this month.
The treatment joins sotrovimab among monoclonal antibodies now available for use in the state of Illinois. The state also has two oral antiviral drugs and a preventative drug that it distributes, IDPH officials said.
“This latest FDA-approved COVID-19 treatment will continue to move us forward as we coexist with COVID-19,” said IDPH Director Dr. Ngozi Ezike. “While vaccination and boosting are still the best protection against serious illness, this new treatment can help keep people out of the hospital.”
The United States Department of Health and Human Services distributes the drug to states, and IDPH officials say they will continue to pursue “equitable distribution” of treatment to high-need and vulnerable communities across the state.
According to officials, bebtelovimab is approved for use in patients who experience mild to moderate COVID symptoms, which have underlying conditions that put them at risk for serious illness.
The treatment is given as an injection and residents are encouraged to ask their nurses if they are eligible for the treatment if they are infected with COVID-19.
More information can be found on IDPH’s website.